Research analysts at Roth Capital dropped their target price on shares of Amarin Co. plc (NASDAQ:AMRN) from $5.00 to $4.00 in a report released on Tuesday, Analyst Ratings News reports. The firm currently has a “buy” rating on the stock. Roth Capital’s target price would indicate a potential upside of 161.44% from the stock’s previous close.
A number of other firms have also recently commented on AMRN. Analysts at Aegis reiterated a “hold” rating on shares of Amarin Co. plc in a research note to investors on Monday, November 11th. Separately, analysts at Canaccord Genuity cut their price target on shares of Amarin Co. plc from $3.00 to $1.60 in a research note to investors on Friday, November 8th. They now have a “hold” rating on the stock. Finally, analysts at MKM Partners cut their price target on shares of Amarin Co. plc from $5.00 to $2.50 in a research note to investors on Friday, November 8th. They now have a “buy” rating on the stock. Ten equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Amarin Co. plc currently has a consensus rating of “Hold” and an average price target of $5.55.
Shares of Amarin Co. plc (NASDAQ:AMRN) traded up 24.84% on Tuesday, hitting $1.91. 15,906,654 shares of the company’s stock traded hands. Amarin Co. plc has a 52-week low of $1.36 and a 52-week high of $12.90. The stock’s 50-day moving average is $3.38 and its 200-day moving average is $5.53. The company’s market cap is $325.1 million.
Amarin Co. plc (NASDAQ:AMRN) last announced its earnings results on Thursday, November 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.07. The company had revenue of $8.40 million for the quarter, compared to the consensus estimate of $10.25 million. On average, analysts predict that Amarin Co. plc will post $-1.22 earnings per share for the current fiscal year.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.